Foghorn offers asymmetric precision-oncology upside through a Lilly-validated chromatin platform, but its fate hinges on early clinical proof, partner commitment, and dilution discipline.
Overview
Foghorn Therapeutics is a clinical-stage precision oncology company targeting chromatin regulatory dysfunction through its Gene Traffic Control platform. Its lead asset, FHD-909, is a Lilly-partnered selective SMARCA2 inhibitor for SMARCA4-mutated tumors, supported by a 50/50 U.S. economics structure and ex-U.S. royalties. Wholly owned CBP, EP300, and ARID1B degrader programs provide upside beyond the partnership. The company has no product revenue, relies on collaboration income and milestones, and offers high scientific upside paired with meaningful clinical, financing, and execution risk.